Back to Search Start Over

Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016-2020.

Authors :
Vold, Jørn Henrik
Gjestad, Rolf
Aas, Christer F.
Chalabianloo, Fatemeh
Skurtveit, Svetlana
Løberg, Else-Marie
Johansson, Kjell Arne
Fadnes, Lars Thore
for the INTRO-HCV Study Group
Buljovcic, Vibeke Bråthen
Daltveit, Jan Tore
Alpers, Silvia Eiken
Fadnes, Lars T.
Eriksen, Trude Fondenes
Gundersen, Per
Hille, Velinda
Håberg, Kristin Holmelid
Leiva, Rafael Alexander
Carlsen, Siv-Elin Leirvåg
Bonnier, Martine Lepsøy
Source :
Substance Abuse Treatment, Prevention & Policy. 12/14/2020, Vol. 15 Issue 1, p1-11. 11p.
Publication Year :
2020

Abstract

<bold>Background: </bold>The impact of clinical and sociodemographic factors on fatigue remains unknown among patients with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item fatigue severity scale (FSS-9) and identify the impact that clinical and sociodemographic factors - such as injecting substance use, chronic infectious diseases, liver fibrosis, opioid agonist therapy (OAT), debt difficulties, and housing situation - have on fatigue.<bold>Methods: </bold>We used data from a cohort of patients with SUD in Norway with annual health assessments surveying FSS-9 and some clinical and sociodemographic factors. A total of 915 FSS-9 measurements were collected from 654 patients during the period 2016-2020. We defined baseline as the first annual health assessment when the health assessments were listed chronologically. Time was defined as years from baseline. We used a linear mixed model to analyse whether the clinical and sociodemographic factors affected the FSS-9 sum score, presented with beta coefficients (β) with 95% confidence intervals (CI).<bold>Results: </bold>The mean sum score of the FSS-9 was 43 (standard deviation: 16) at baseline. Females compared with males (adjusted mean difference of FSS-9 sum score: 4.1, 95% CI: 1.3-7.0), having debt difficulties compared with having no debt difficulties (2.9;0.4-5.3), and frequent use of benzodiazepines (5.7;3.0-8.4) or amphetamines (-5.0;-8.0- -2.0) compared to less frequent or no use of these substances changed the FSS-9 baseline sum score. The other clinical and sociodemographic factors did not predict any clinically relevant change in the FSS-9 sum score from baseline to the following health assessments.<bold>Conclusion: </bold>Patients with SUD suffer from high levels of fatigue. Female patients, patients with debt difficulties, and those with extensive use of benzodiazepines are at particular risk of being fatigued. This should be taken into consideration when planning health services. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1747597X
Volume :
15
Issue :
1
Database :
Academic Search Index
Journal :
Substance Abuse Treatment, Prevention & Policy
Publication Type :
Academic Journal
Accession number :
147605559
Full Text :
https://doi.org/10.1186/s13011-020-00334-x